Health & Fitness
Wed, September 5, 2012
BETHESDA, Md.--([ BUSINESS WIRE ])--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that management will present at two upcoming investment conferences:
- Dr. Ryuji Ueno, Chair and Chief Executive Officer of Sucampo, will present at the BioCentury-Thomson Reuters NewsMakers in the Biotech Industry Conference, in New York, on Friday, September 7, at 1:30 pm Eastern Time.
- Mr. Cary J. Claiborne, CFO of Sucampo, will present at the Rodman & Renshaw Annual Global Investment Conference, in New York on Monday, September 10, at 2pm Eastern Time.
The presentations will be webcast live and may be accessed from the Event Calendar page of Sucampoas website at [ http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar ]. A replay of each webcast will be available on the Companyas website for several days after the live events. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit [ www.sucampo.com ].
Sucampo Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's Form 10-Q for the quarter ended May 10, 2012, which the Company incorporates by reference.
